Clin Exp Vaccine Res.  2014 Jul;3(2):149-154. 10.7774/cevr.2014.3.2.149.

Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo

• Park CG

• KMID: 1730619
• DOI: http://doi.org/10.7774/cevr.2014.3.2.149

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells capable of initiating and regulating innate and adaptive immunity. The development of effective ways to produce a large number of DCs in laboratories made the use of DCs available in various vaccine approaches. Compared to conventional vaccines, focused on protective antibody responses, DC vaccines emphasize protective T cell immunity but might elicit strong antibody responses as well. In addition, the recent discoveries of functionally distinct DC subsets in various organs and tissues are likely to increase the potential of exploiting DCs in vaccines and immunotherapy. Vaccines composed of DCs generated ex vivo, pulsed with antigens, and matured prior to being re-infused to the body have been widely tried clinically but resulted in limited success due to various obstacles. In this review, new approaches that protein vaccines are selectively targeted to the endocytic C-type lectin receptors on surface of DCs in vivo are discussed.

Keyword

Antigen receptor; C-type lectins; Dendritic cells; Monoclonal antibody

MeSH Terms

Adaptive Immunity
Antibody Formation
Antigen-Presenting Cells
Dendritic Cells*
Immunotherapy
Lectins, C-Type*
Receptors, Antigen
Vaccines
Lectins, C-Type
Receptors, Antigen
Vaccines

Figure

• 

  Fig. 1 Analyses of human immunodeficiency virus Gag proteins expressed from mammalian CHO cells. (A) Soluble, FLAG-tagged Gag p41 and p24 proteins were produced into culture media from the stably transfected CHO cells, followed by anti-FLAG affinity purification. Left panel: Five micrograms each of purified p41 and p24 was subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis with/without (+/-) treatment of β-mercaptoethanol (BME) and boiling at 100℃ for 5 minutes (Boiling). After electrophoresis, the gel was visualized with Coomassie blue stain. Aggregates on the border between stacking and resolving gels and on the bottom of loading wells are detected from the purified p41 without BME & Boiling. Right panel: Zero point five microgram each of purified p41 and p24 was subjected to SDS-polyacrylamide gel electrophoresis with/without BME & Boiling. After electrophoresis, the gel was transferred onto polyvinylidene difluoride (PVDF) membrane, blotted with anti-Gag antibody, and visualized with chemiluminescent reagent. Aggregates with high molecular weight are detected from the purified p41 without BME & Boiling. (B) Culture supernatants from stably transfected CHO cells expressing soluble, FLAG-tagged Gag p41 and p24 proteins were analyzed. Five microliters each of cell culture supernatants was subjected to SDS-polyacrylamide gel electrophoresis with/without BME & Boiling. After electrophoresis, the gel was transferred onto PVDF membrane, blotted with anti-Gag antibody, and visualized with chemiluminescent reagent. Aggregates with high molecular weight are detected from the cell culture supernatant of p41 without BME & Boiling.

Reference

1. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 2008; 29:319–324.

2. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012; 30:1–22.

3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245–252.

4. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell. 2001; 106:271–274.

5. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007; 449:419–426.

6. Trumpfheller C, Longhi MP, Caskey M, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med. 2012; 271:183–192.

7. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685–711.

8. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363:411–422.

9. Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Ann N Y Acad Sci. 2013; 1284:31–45.

10. Kraal G, Breel M, Janse M, Bruin G. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J Exp Med. 1986; 163:981–997.

11. Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995; 375:151–155.

12. Mahnke K, Guo M, Lee S, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol. 2000; 151:673–684.

13. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002; 196:1627–1638.

14. Lahoud MH, Ahmet F, Zhang JG, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A. 2012; 109:16270–16275.

15. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001; 194:769–779.

16. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity. 2004; 20:695–705.

17. Bonifaz LC, Bonnyay DP, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004; 199:815–824.

18. Trumpfheller C, Finke JS, Lopez CB, et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med. 2006; 203:607–617.

19. Bozzacco L, Trumpfheller C, Siegal FP, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007; 104:1289–1294.

20. Do Y, Koh H, Park CG, et al. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol. 2010; 40:2791–2796.

21. Trumpfheller C, Caskey M, Nchinda G, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A. 2008; 105:2574–2579.

22. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009; 206:1589–1602.

23. Caskey M, Lefebvre F, Filali-Mouhim A, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011; 208:2357–2366.

24. Guo M, Gong S, Maric S, et al. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol. 2000; 61:729–738.

25. Kato M, McDonald KJ, Khan S, et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol. 2006; 18:857–869.

26. Cheong C, Choi JH, Vitale L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood. 2010; 116:3828–3838.

27. Park CG, Rodriguez A, Ueta H, et al. Generation of anti-human DEC205/CD205 monoclonal antibodies that recognize epitopes conserved in different mammals. J Immunol Methods. 2012; 377:15–22.

28. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007; 315:107–111.

29. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 2010; 143:416–429.

30. Cheong C, Matos I, Choi JH, et al. New monoclonal anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. J Immunol Methods. 2010; 360:66–75.

31. Gardner JM, Metzger TC, McMahon EJ, et al. Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4(+) T cells. Immunity. 2013; 39:560–572.

32. Flynn BJ, Kastenmuller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A. 2011; 108:7131–7136.